News

VIDEO: Investigational combo stalls progression in recurrent ovarian cancer


 

AT THE ASCO ANNUAL MEETING 2014

CHICAGO – Combining two oral investigational agents, cediranib and olaparib, significantly delayed progression in recurrent ovarian cancer from 9 months with olaparib alone to 17.7 months in a phase II study.

This is the first time this strategy of coupling a PARP (poly ADP ribose polymerase) inhibitor (olaparib) with an antiangiogenesis drug (cediranib) has ever been tested in a clinical trial for ovarian cancer.

If validated, the targeted drug combination could potentially provide women with recurrent ovarian cancer an alternative to standard chemotherapy, according to lead author Dr. Joyce F. Liu of Dana-Farber Cancer Institute, Boston.

We caught up with Dr. Liu at this year’s annual meeting of the American Society of Clinical Oncology, where the study was formally presented.

Dr. Liu reported having no financial disclosures. The study was supported by the National Cancer Institute and National Institutes of Health.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

pwendling@frontlinemedcom.com

Recommended Reading

Vaginal cuff brachytherapy plus chemotherapy no better than pelvic radiation in early endometrial cancer
MDedge Hematology and Oncology
Launch of rare-cancer trial spurs many more
MDedge Hematology and Oncology
Palliative care consultations improve outcomes, but referrals lag
MDedge Hematology and Oncology
Study suggests robotics have altered hysterectomy landscape
MDedge Hematology and Oncology
First ASCO survivor care guidelines tackle fatigue, anxiety/depression, neuropathy
MDedge Hematology and Oncology
P4 Medicine: A new approach to health and disease
MDedge Hematology and Oncology
Topical lidocaine reduces menopausal dyspareunia
MDedge Hematology and Oncology
AUDIO: Challenges, rewards face creators of pediatric oncofertility clinics
MDedge Hematology and Oncology
Cobas HPV test for first-line screening for cervical cancer
MDedge Hematology and Oncology
ASCO: Extend adjuvant endocrine therapy to 10 years
MDedge Hematology and Oncology